Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug

Last November, I initiated coverage on Vertex Pharmaceutical Inc. (NASDAQ: VRTX ) suggesting the stock as a strong buy around $461/share. This was due to the commercialization potential of three drugs, namely CASGEVY, JOURNAVX (suzetrigine) and ALYFTREK (vanzacaftor triple). In mid-December Vertex saw a volatile period punctuatedBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).- ...